Informações: Esta não é a versão mais recente do modelo de dados. Uma visão geral da versão pode ser encontrada à esquerda em Versões. Para a versão mais recente, clique aqui.
Informações:
Falhas:
ID
39816
Descrição
The Efficacy of 5-fluorouracil/Mitomycin for the Patients With Pulmonary Metastasis of Hepatocellular Carcinoma; ODM derived from: https://clinicaltrials.gov/show/NCT01953406
Link
https://clinicaltrials.gov/show/NCT01953406
Palavras-chave
Versões (2)
- 23/02/2020 23/02/2020 -
- 27/09/2021 27/09/2021 -
Titular dos direitos
See clinicaltrials.gov
Transferido a
23 de fevereiro de 2020
DOI
Para um pedido faça login.
Licença
Creative Commons BY 4.0
Comentários do modelo :
Aqui pode comentar o modelo. Pode comentá-lo especificamente através dos balões de texto nos grupos de itens e itens.
Comentários do grupo de itens para :
Comentários do item para :
Para descarregar formulários, precisa de ter uma sessão iniciada. Por favor faça login ou registe-se gratuitamente.
Eligibility Hepatocellular Carcinoma NCT01953406
Eligibility Hepatocellular Carcinoma NCT01953406
- StudyEvent: Eligibility
Similar models
Eligibility Hepatocellular Carcinoma NCT01953406
- StudyEvent: Eligibility
Name
Tipo
Description | Question | Decode (Coded Value)
Tipo de dados
Alias
Local Therapy Liver carcinoma intrahepatic | Radiofrequency ablation | Ethanol Ablation Therapy | Cryosurgery | Operative Surgical Procedures | Excision | Tumor intrahepatic Absent | CT of Liver | MRI of Liver
Item
patients who have received previous local therapy treatments for the intrahepatic hepatocellular carcinoma (rfa, pei, cryoablation, surgery, resection) and who don't have any viable intrahepatic tumor within 3 months of imaging (dynamic liver ct or liver mri) after the locoregional therapy
boolean
C1517925 (UMLS CUI [1,1])
C2239176 (UMLS CUI [1,2])
C1512948 (UMLS CUI [1,3])
C0850292 (UMLS CUI [2])
C1880568 (UMLS CUI [3])
C0010408 (UMLS CUI [4])
C0543467 (UMLS CUI [5])
C0728940 (UMLS CUI [6])
C0027651 (UMLS CUI [7,1])
C1512948 (UMLS CUI [7,2])
C0332197 (UMLS CUI [7,3])
C0412621 (UMLS CUI [8])
C0412694 (UMLS CUI [9])
C2239176 (UMLS CUI [1,2])
C1512948 (UMLS CUI [1,3])
C0850292 (UMLS CUI [2])
C1880568 (UMLS CUI [3])
C0010408 (UMLS CUI [4])
C0543467 (UMLS CUI [5])
C0728940 (UMLS CUI [6])
C0027651 (UMLS CUI [7,1])
C1512948 (UMLS CUI [7,2])
C0332197 (UMLS CUI [7,3])
C0412621 (UMLS CUI [8])
C0412694 (UMLS CUI [9])
Secondary malignant neoplasm of lung Measurable
Item
patients who have measurable lung metastasis
boolean
C0153676 (UMLS CUI [1,1])
C1513040 (UMLS CUI [1,2])
C1513040 (UMLS CUI [1,2])
Sorafenib Previous | Secondary malignant neoplasm of lung Progressive Disease
Item
patients who have received their last dose of sorafenib more than 14 days before and who had progressive disease of lung metastasis with sorafenib
boolean
C1516119 (UMLS CUI [1,1])
C0205156 (UMLS CUI [1,2])
C0153676 (UMLS CUI [2,1])
C1335499 (UMLS CUI [2,2])
C0205156 (UMLS CUI [1,2])
C0153676 (UMLS CUI [2,1])
C1335499 (UMLS CUI [2,2])
Risk factors Liver carcinoma | Hepatitis B, Chronic | Hepatitis C, Chronic | Liver Cirrhosis
Item
patients who have risk factors of hepatocellular carcinoma (chronic hepatitis b, chronic hepatitis c, liver cirrhosis)
boolean
C0035648 (UMLS CUI [1,1])
C2239176 (UMLS CUI [1,2])
C0524909 (UMLS CUI [2])
C0524910 (UMLS CUI [3])
C0023890 (UMLS CUI [4])
C2239176 (UMLS CUI [1,2])
C0524909 (UMLS CUI [2])
C0524910 (UMLS CUI [3])
C0023890 (UMLS CUI [4])
Age
Item
age : 18 years to 80 years
boolean
C0001779 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status of 0 to 2
boolean
C1520224 (UMLS CUI [1])
Child-Pugh Classification | Child-Pugh Score
Item
child-pugh class a,b (child-pugh score 5-9)
boolean
C2347612 (UMLS CUI [1])
C4055253 (UMLS CUI [2])
C4055253 (UMLS CUI [2])
Bone Marrow function | Laboratory Requirement
Item
adequate bone marrow, liver function as assessed by the following laboratory requirements to be conducted within 7 days prior to screening:
boolean
C0005953 (UMLS CUI [1,1])
C0031843 (UMLS CUI [1,2])
C0022885 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
C0031843 (UMLS CUI [1,2])
C0022885 (UMLS CUI [2,1])
C1514873 (UMLS CUI [2,2])
White Blood Cell Count procedure
Item
wbc count > 1,000/mm3
boolean
C0023508 (UMLS CUI [1])
Absolute neutrophil count
Item
absolute neutrophil count > 500/mm3
boolean
C0948762 (UMLS CUI [1])
Hemoglobin measurement
Item
hb > 7.0 g/dl
boolean
C0518015 (UMLS CUI [1])
Platelet Count measurement
Item
platelet count > 50,000 /mm3
boolean
C0032181 (UMLS CUI [1])
Serum total bilirubin measurement
Item
bilirubin < 3 mg/dl
boolean
C1278039 (UMLS CUI [1])
Clotting function | International Normalized Ratio
Item
adequate clotting function: inr < 2.3 or < 6sec
boolean
C0005778 (UMLS CUI [1])
C0525032 (UMLS CUI [2])
C0525032 (UMLS CUI [2])
Child-Pugh Score
Item
child-pugh score > 10
boolean
C4055253 (UMLS CUI [1])
ECOG performance status
Item
ecog performance status > 3
boolean
C1520224 (UMLS CUI [1])
Organ allograft
Item
history of organ allograft
boolean
C0178784 (UMLS CUI [1,1])
C0040739 (UMLS CUI [1,2])
C0040739 (UMLS CUI [1,2])
Comorbidity Uncontrolled | Treatment required
Item
patients with uncontrolled co-morbidity which needs treatment
boolean
C0009488 (UMLS CUI [1,1])
C0205318 (UMLS CUI [1,2])
C0332121 (UMLS CUI [2])
C0205318 (UMLS CUI [1,2])
C0332121 (UMLS CUI [2])
Systemic Chemotherapy | Exception Sorafenib
Item
patients who have received prior systemic chemotherapy except sorafenib
boolean
C1883256 (UMLS CUI [1])
C1705847 (UMLS CUI [2,1])
C1516119 (UMLS CUI [2,2])
C1705847 (UMLS CUI [2,1])
C1516119 (UMLS CUI [2,2])